S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
20 mars 2020 uppdaterad av: Southwest Oncology Group
A Phase II Trial of the Combination of OSI-774 (ERLOTINIB; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features (ADENOBAC)
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving erlotinib together with bevacizumab may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving erlotinib together with bevacizumab works in treating patients with stage III or stage IV non-small cell lung cancer.
Studieöversikt
Status
Avslutad
Betingelser
Intervention / Behandling
Detaljerad beskrivning
OBJECTIVES:
Primary
- Determine overall survival of patients with stage IIIB or IV bronchioloalveolar carcinoma (BAC) or adenocarcinoma with BAC features treated with erlotinib hydrochloride and bevacizumab.
Secondary
- Determine the progression-free survival of patients treated with this regimen.
- Compare, preliminarily, response as assessed by RECIST criteria vs response as assessed by a central computer-assisted image-analysis system in patients with measurable disease treated with this regimen.
- Assess the frequency and severity of toxicities of this regimen in these patients.
OUTLINE: This is a multicenter study.
Patients receive oral erlotinib hydrochloride once daily on days 1-21 and bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 3 months for 1 year and then every 6 months for up to 2 years.
PROJECTED ACCRUAL: A total of 80 patients will be accrued for this study.
Studietyp
Interventionell
Inskrivning (Faktisk)
84
Fas
- Fas 2
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
California
-
Antioch, California, Förenta staterna, 94531
- Kaiser Permanente - Deer Valley
-
Berkeley, California, Förenta staterna, 94704
- Alta Bates Summit Comprehensive Cancer Center
-
Burlingame, California, Förenta staterna, 94010
- Peninsula Medical Center
-
Fremont, California, Förenta staterna, 94538
- Kaiser Permanente - Fremont
-
Hayward, California, Förenta staterna, 94545
- Kaiser Permanente Medical Center - Hayward
-
Marysville, California, Förenta staterna, 95901
- Tibotec Therapeutics - Division of Ortho Biotech Products, LP
-
Oakland, California, Förenta staterna, 94611
- Kaiser Permanente Medical Center - Oakland
-
Pleasanton, California, Förenta staterna, 94588
- Valley Medical Oncology Consultants - Pleasanton
-
Redwood City, California, Förenta staterna, 94063
- Kaiser Permanente Medical Center - Redwood City
-
Richmond, California, Förenta staterna, 94801
- Kaiser Permanente Medical Center - Richmond
-
Roseville, California, Förenta staterna, 95661
- Kaiser Permanente Medical Center - Roseville
-
Sacramento, California, Förenta staterna, 95817
- University of California Davis Cancer Center
-
Sacramento, California, Förenta staterna, 95823
- South Sacramento Kaiser-Permanente Medical Center
-
Sacramento, California, Förenta staterna, 95825
- Kaiser Permanente Medical Center - Sacramento
-
San Francisco, California, Förenta staterna, 94115
- Kaiser Permanente Medical Center - San Francisco Geary Campus
-
San Francisco, California, Förenta staterna, 94118
- California Pacific Medical Center - California Campus
-
San Jose, California, Förenta staterna, 95119
- Kaiser Permanente Medical Center - Santa Teresa
-
San Rafael, California, Förenta staterna, 94903
- Sutter Health - Western Division Cancer Research Group
-
San Rafael, California, Förenta staterna, 94903
- Kaiser Foundation Hospital - San Rafael
-
Santa Clara, California, Förenta staterna, 95051
- Kaiser Permanente Medical Center - Santa Clara Kiely Campus
-
Santa Rosa, California, Förenta staterna, 95403
- Kaiser Permanente Medical Center - Santa Rosa
-
South San Francisco, California, Förenta staterna, 94080
- Kaiser Permanente Medical Center - South San Francisco
-
Stockton, California, Förenta staterna, 95210
- Kaiser Permanente Medical Facility - Stockton
-
Truckee, California, Förenta staterna, 96161
- Tahoe Forest Cancer Center
-
Vacaville, California, Förenta staterna, 95688
- Kaiser Permanente Medical Center - Vacaville
-
Vallejo, California, Förenta staterna, 94589
- Sutter Solano Medical Center
-
Vallejo, California, Förenta staterna, 94589
- Kaiser Permanente Medical Center - Vallejo
-
Walnut Creek, California, Förenta staterna, 94596
- Kaiser Permanente Medical Center - Walnut Creek
-
-
Connecticut
-
Hartford, Connecticut, Förenta staterna, 06105
- Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
-
-
Georgia
-
Atlanta, Georgia, Förenta staterna, 30309
- Piedmont Hospital
-
Atlanta, Georgia, Förenta staterna, 30342-1611
- Northside Hospital Cancer Center
-
Atlanta, Georgia, Förenta staterna, 30342-1701
- Saint Joseph's Hospital of Atlanta
-
Atlanta, Georgia, Förenta staterna, 30342
- CCOP - Atlanta Regional
-
Austell, Georgia, Förenta staterna, 30106
- WellStar Cobb Hospital
-
Columbus, Georgia, Förenta staterna, 31904
- John B. Amos Cancer Center
-
Decatur, Georgia, Förenta staterna, 30033
- Charles B. Eberhart Cancer Center at DeKalb Medical Center
-
Fayetteville, Georgia, Förenta staterna, 30214
- Piedmont Fayette Hospital
-
Gainesville, Georgia, Förenta staterna, 30501
- Northeast Georgia Medical Center
-
Lawrenceville, Georgia, Förenta staterna, 30045
- Gwinnett Medical Center
-
Marietta, Georgia, Förenta staterna, 30060
- Kennestone Cancer Center at Wellstar Kennestone Hospital
-
Riverdale, Georgia, Förenta staterna, 30274-2600
- Southern Regional Medical Center
-
Rome, Georgia, Förenta staterna, 30165
- Harbin Clinic Cancer Center - Medical Oncology
-
-
Hawaii
-
Honolulu, Hawaii, Förenta staterna, 96819
- Kaiser Permanente - Moanalua Medical Center and Clinic
-
-
Illinois
-
Decatur, Illinois, Förenta staterna, 62526
- Decatur Memorial Hospital Cancer Care Institute
-
Maywood, Illinois, Förenta staterna, 60153
- Cardinal Bernardin Cancer Center at Loyola University Medical Center
-
Springfield, Illinois, Förenta staterna, 62781-0001
- Regional Cancer Center at Memorial Medical Center
-
-
Kansas
-
Chanute, Kansas, Förenta staterna, 66720
- Cancer Center of Kansas, PA - Chanute
-
Dodge City, Kansas, Förenta staterna, 67801
- Cancer Center of Kansas, PA - Dodge City
-
El Dorado, Kansas, Förenta staterna, 67042
- Cancer Center of Kansas, PA - El Dorado
-
Fort Scott, Kansas, Förenta staterna, 66701
- Cancer Center of Kansas - Fort Scott
-
Independence, Kansas, Förenta staterna, 67301
- Cancer Center of Kansas-Independence
-
Kingman, Kansas, Förenta staterna, 67068
- Cancer Center of Kansas, PA - Kingman
-
Lawrence, Kansas, Förenta staterna, 66044
- Lawrence Memorial Hospital
-
Liberal, Kansas, Förenta staterna, 67901
- Cancer Center of Kansas, PA - Liberal
-
Newton, Kansas, Förenta staterna, 67114
- Cancer Center of Kansas, PA - Newton
-
Parsons, Kansas, Förenta staterna, 67357
- Cancer Center of Kansas, PA - Parsons
-
Pratt, Kansas, Förenta staterna, 67124
- Cancer Center of Kansas, PA - Pratt
-
Salina, Kansas, Förenta staterna, 67401
- Cancer Center of Kansas, PA - Salina
-
Salina, Kansas, Förenta staterna, 67401
- Tammy Walker Cancer Center at Salina Regional Health Center
-
Topeka, Kansas, Förenta staterna, 66606
- Cotton-O'Neil Cancer Center
-
Wellington, Kansas, Förenta staterna, 67152
- Cancer Center of Kansas, PA - Wellington
-
Wichita, Kansas, Förenta staterna, 67208
- Cancer Center of Kansas, PA - Medical Arts Tower
-
Wichita, Kansas, Förenta staterna, 67214
- Cancer Center of Kansas, PA - Wichita
-
Wichita, Kansas, Förenta staterna, 67214
- CCOP - Wichita
-
Wichita, Kansas, Förenta staterna, 67214
- Via Christi Cancer Center at Via Christi Regional Medical Center
-
Wichita, Kansas, Förenta staterna, 67208
- Associates in Womens Health, PA - North Review
-
Winfield, Kansas, Förenta staterna, 67156
- Cancer Center of Kansas, PA - Winfield
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna, 40536-0093
- Lucille P. Markey Cancer Center at University of Kentucky
-
-
Michigan
-
Ann Arbor, Michigan, Förenta staterna, 48106-0995
- Saint Joseph Mercy Cancer Center
-
Ann Arbor, Michigan, Förenta staterna, 48106
- CCOP - Michigan Cancer Research Consortium
-
Battle Creek, Michigan, Förenta staterna, 49017
- Battle Creek Health System Cancer Care Center
-
Big Rapids, Michigan, Förenta staterna, 49307
- Mecosta County Medical Center
-
Dearborn, Michigan, Förenta staterna, 48123-2500
- Oakwood Cancer Center at Oakwood Hospital and Medical Center
-
Flint, Michigan, Förenta staterna, 48503
- Hurley Medical Center
-
Flint, Michigan, Förenta staterna, 48503
- Genesys Hurley Cancer Institute
-
Grand Blanc, Michigan, Förenta staterna, 48439
- Genesys Regional Medical Center
-
Grand Rapids, Michigan, Förenta staterna, 49503
- Butterworth Hospital at Spectrum Health
-
Grand Rapids, Michigan, Förenta staterna, 49503
- CCOP - Grand Rapids
-
Grand Rapids, Michigan, Förenta staterna, 49503
- Lacks Cancer Center at Saint Mary's Health Care
-
Grosse Pointe Woods, Michigan, Förenta staterna, 48236
- Van Elslander Cancer Center at St. John Hospital and Medical Center
-
Jackson, Michigan, Förenta staterna, 49201
- Foote Memorial Hospital
-
Lansing, Michigan, Förenta staterna, 48912-1811
- Sparrow Regional Cancer Center
-
Livonia, Michigan, Förenta staterna, 48154
- St. Mary Mercy Hospital
-
Muskegon, Michigan, Förenta staterna, 49443
- Mercy General Health Partners
-
Pontiac, Michigan, Förenta staterna, 48341-2985
- St. Joseph Mercy Oakland
-
Port Huron, Michigan, Förenta staterna, 48060
- Mercy Regional Cancer Center at Mercy Hospital
-
Saginaw, Michigan, Förenta staterna, 48601
- Seton Cancer Institute at Saint Mary's - Saginaw
-
Traverse City, Michigan, Förenta staterna, 49684
- Munson Medical Center
-
Warren, Michigan, Förenta staterna, 48093
- St. John Macomb Hospital
-
Wyoming, Michigan, Förenta staterna, 49519
- Metro Health Hospital
-
-
Montana
-
Billings, Montana, Förenta staterna, 59101
- CCOP - Montana Cancer Consortium
-
Billings, Montana, Förenta staterna, 59101
- St. Vincent Healthcare Cancer Care Services
-
Billings, Montana, Förenta staterna, 59107-7000
- Billings Clinic - Downtown
-
Billings, Montana, Förenta staterna, 59102
- Hematology-Oncology Centers of the Northern Rockies - Billings
-
Bozeman, Montana, Förenta staterna, 59715
- Bozeman Deaconess Cancer Center
-
Butte, Montana, Förenta staterna, 59701
- St. James Healthcare Cancer Care
-
Great Falls, Montana, Förenta staterna, 59405
- Great Falls Clinic - Main Facility
-
Great Falls, Montana, Förenta staterna, 59405-5309
- Big Sky Oncology
-
Great Falls, Montana, Förenta staterna, 59405
- Sletten Cancer Institute at Benefis Healthcare
-
Havre, Montana, Förenta staterna, 59501
- Northern Montana Hospital
-
Helena, Montana, Förenta staterna, 59601
- St. Peter's Hospital
-
Kalispell, Montana, Förenta staterna, 59901
- Kalispell Regional Medical Center
-
Kalispell, Montana, Förenta staterna, 59901
- Glacier Oncology, PLLC
-
Kalispell, Montana, Förenta staterna, 59901
- Kalispell Medical Oncology at KRMC
-
Missoula, Montana, Förenta staterna, 59807-7877
- Montana Cancer Specialists at Montana Cancer Center
-
Missoula, Montana, Förenta staterna, 59807
- Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
-
-
North Carolina
-
Goldsboro, North Carolina, Förenta staterna, 27534
- Wayne Memorial Hospital, Incorporated
-
Hendersonville, North Carolina, Förenta staterna, 28791
- Pardee Memorial Hospital
-
-
Ohio
-
Bellefontaine, Ohio, Förenta staterna, 43311
- Mary Rutan Hospital
-
Chillicothe, Ohio, Förenta staterna, 45601
- Adena Regional Medical Center
-
Columbus, Ohio, Förenta staterna, 43214-3998
- Riverside Methodist Hospital Cancer Care
-
Columbus, Ohio, Förenta staterna, 43222
- Mount Carmel Health - West Hospital
-
Columbus, Ohio, Förenta staterna, 43215
- CCOP - Columbus
-
Columbus, Ohio, Förenta staterna, 43215
- Grant Medical Center Cancer Care
-
Columbus, Ohio, Förenta staterna, 43228
- Doctors Hospital at Ohio Health
-
Delaware, Ohio, Förenta staterna, 43015
- Grady Memorial Hospital
-
Lancaster, Ohio, Förenta staterna, 43130
- Fairfield Medical Center
-
Marietta, Ohio, Förenta staterna, 45750
- Strecker Cancer Center at Marietta Memorial Hospital
-
Mount Vernon, Ohio, Förenta staterna, 43050
- Knox Community Hospital
-
Newark, Ohio, Förenta staterna, 43055
- Licking Memorial Cancer Care Program at Licking Memorial Hospital
-
Springfield, Ohio, Förenta staterna, 45505
- Community Hospital of Springfield and Clark County
-
Westerville, Ohio, Förenta staterna, 43081
- Mount Carmel St. Ann's Cancer Center
-
Zanesville, Ohio, Förenta staterna, 43701
- Genesis - Good Samaritan Hospital
-
-
South Carolina
-
Charleston, South Carolina, Förenta staterna, 29425
- Hollings Cancer Center at Medical University of South Carolina
-
-
Utah
-
American Fork, Utah, Förenta staterna, 84003
- American Fork Hospital
-
Cedar City, Utah, Förenta staterna, 84720
- Sandra L. Maxwell Cancer Center
-
Logan, Utah, Förenta staterna, 84321
- Logan Regional Hospital
-
Murray, Utah, Förenta staterna, 84157
- Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
-
Ogden, Utah, Förenta staterna, 84403
- Val and Ann Browning Cancer Center at McKay-Dee Hospital Center
-
Provo, Utah, Förenta staterna, 84604
- Utah Valley Regional Medical Center - Provo
-
Saint George, Utah, Förenta staterna, 84770
- Dixie Regional Medical Center - East Campus
-
Salt Lake City, Utah, Förenta staterna, 84143
- LDS Hospital
-
Salt Lake City, Utah, Förenta staterna, 84106
- Utah Cancer Specialists at UCS Cancer Center
-
-
Washington
-
Bellingham, Washington, Förenta staterna, 98225
- St. Joseph Cancer Center
-
Bremerton, Washington, Förenta staterna, 98310
- Olympic Hematology and Oncology
-
Kennewick, Washington, Förenta staterna, 99336
- Columbia Basin Hematology
-
Mount Vernon, Washington, Förenta staterna, 98274
- Skagit Valley Hospital Cancer Care Center
-
Poulsbo, Washington, Förenta staterna, 98370
- Harrison Poulsbo Hematology and Onocology
-
Seattle, Washington, Förenta staterna, 98109
- Fred Hutchinson Cancer Research Center
-
Seattle, Washington, Förenta staterna, 98104
- Harborview Medical Center
-
Seattle, Washington, Förenta staterna, 98104
- Minor and James Medical, PLLC
-
Seattle, Washington, Förenta staterna, 98112
- Group Health Central Hospital
-
Seattle, Washington, Förenta staterna, 98122-4307
- Swedish Cancer Institute at Swedish Medical Center - First Hill Campus
-
Seattle, Washington, Förenta staterna, 98195
- University Cancer Center at University of Washington Medical Center
-
Spokane, Washington, Förenta staterna, 99202
- Cancer Care Northwest - Spokane South
-
Spokane, Washington, Förenta staterna, 99218
- Evergreen Hematology and Oncology, PS
-
Wenatchee, Washington, Förenta staterna, 98801-2028
- Wenatchee Valley Medical Center
-
-
Wyoming
-
Sheridan, Wyoming, Förenta staterna, 82801
- Welch Cancer Center at Sheridan Memorial Hospital
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 120 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
DISEASE CHARACTERISTICS:
Biopsy-proven* bronchioloalveolar carcinoma (BAC) or BAC variants (e.g., adenocarcinoma with BAC features, BAC with invasive adenocarcinoma) meeting the following criteria:
- Incompletely resected or unresectable disease
- No component of squamous cell carcinoma
Disease staged as 1 of the following:
- Stage IIIB disease (T4 [cytologically confirmed malignant pleural effusion OR pleural tumor foci that are separate from direct pleural invasion by the primary tumor], any N, M0)
Stage IV disease (any T, any N, M1 [distant metastases present])
- Recurrent disease in a separate lobe after prior resection within the past 5 years; multifocal lesions in > 1 lobe; or any disease that is recurrent after surgery or radiotherapy is considered stage IV disease
- Tumor may be multifocal or diffuse NOTE: *Cytology specimens, including bronchial brushing, washings, or fine needle aspiration specimens, alone are not acceptable for diagnosis
Measurable or nonmeasurable disease by chest CT scan
- Pleural effusions, ascites, and laboratory parameters are not acceptable as only evidence of disease
- Disease must be present outside field of prior radiotherapy OR a new lesion must be inside port
- Treated brain metastases allowed provided the patient is asymptomatic and do not require steroids
PATIENT CHARACTERISTICS:
- Zubrod performance status 0-2
- Absolute neutrophil count ≥ 1,500/mm³
- Platelet count ≥ 100,000/mm³
- Total bilirubin normal
- AST or AST ≤ 2.5 times upper limit of normal (ULN) (5 times ULN if liver metastases are present)
- Alkaline phosphatase ≤ 2.5 times ULN (5 times ULN if bone metastases are present)
- Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 50 mL/min
- Urine protein:creatinine ratio ≤ 0.5 OR urine protein < 1 g by 24-hour urine collection
- Willing to provide prior smoking history
- No hemoptysis ≥ ½ teaspoon within the past 28 days
- No clinical history of pulmonary or upper respiratory hemorrhage > grade 2 within the past 6 months or > grade 1 within the past 28 days
- No history of thromboses or hemorrhage, including hemorrhagic or thrombotic stroke, or other CNS bleeding
- No uncontrolled hypertension
- No serious nonhealing wound, ulcer, or bone fracture
No other prior malignancy except for any of the following:
- Adequately treated basal cell or squamous cell skin cancer
- In situ cervical cancer
- Adequately treated stage I or II cancer that is currently in complete remission
- Any other cancer from which the patient has been disease free for 5 years
- Not pregnant or nursing
- Fertile patients must use effective contraception
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- Recovered from prior therapy
- At least 28 days since prior radiotherapy (14 days for palliative radiotherapy)
- At least 28 days since prior surgery (thoracic or other major surgeries)
- More than 7 days since prior fine-needle aspiration or core biopsy
- At least 28 days since prior systemic chemotherapy or biologic therapy
- No prior gefitinib hydrochloride, erlotinib hydrochloride, or bevacizumab
- No other prior anti-epidermal growth factor receptor or anti-vascular endothelial growth factor therapies
- Concurrent stable, therapeutic anticoagulation therapy allowed (i.e., warfarin or low molecular weight heparin), provided the patient has no history of bleeding complications on anticoagulation or an inability to establish a stable therapeutic regimen for anticoagulation
- No other concurrent anticancer therapy, including surgery, chemotherapy, hormone therapy, biologic therapy, or radiotherapy
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Erlotinib and Bevacizumab
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Overall Survival
Tidsram: From date of registration to maximum of 3 years
|
From date of registration to maximum of 3 years
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Progression-free Survival
Tidsram: From date of registration to maximum of 3 years
|
From date of registration to maximum of 3 years
|
|
|
Response as Assessed by RECIST Criteria vs Central Computer-assisted Image-analysis System in Patients With Measurable Disease
Tidsram: From date of registration to maximum of 3 years
|
Images for response assessed by the central computer-assisted image-analysis system were never collected.
|
From date of registration to maximum of 3 years
|
|
Frequency and Severity of Toxicities
Tidsram: From date of registration to maximum of 3 years
|
From date of registration to maximum of 3 years
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Samarbetspartners
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Allmänna publikationer
- West HJ, Moon J, Hirsch FR, et al.: SWOG S0635 and S0636: Phase II trials in advanced-stage NSCLC of erlotinib (OSI-774) and bevacizumab in bronchioloalveolar carcinoma (BAC) and adenocarcinoma with BAC features (adenoBAC), and in never-smokers with primary NSCLC adenocarcinoma (adenoCa). [Abstract] J Clin Oncol 30 (Suppl 15): A-7517, 2012.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 juli 2007
Primärt slutförande (Faktisk)
20 juli 2019
Avslutad studie (Faktisk)
20 augusti 2019
Studieregistreringsdatum
Först inskickad
15 februari 2007
Först inskickad som uppfyllde QC-kriterierna
15 februari 2007
Första postat (Uppskatta)
19 februari 2007
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
2 april 2020
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
20 mars 2020
Senast verifierad
1 mars 2020
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Luftvägssjukdomar
- Neoplasmer efter histologisk typ
- Neoplasmer
- Lungsjukdomar
- Neoplasmer efter plats
- Adenocarcinom
- Carcinom
- Neoplasmer, körtel och epitel
- Neoplasmer i andningsvägarna
- Thoracic neoplasmer
- Adenocarcinom i lungan
- Lungneoplasmer
- Adenokarcinom, bronkiolo-alveolär
- Läkemedels fysiologiska effekter
- Molekylära mekanismer för farmakologisk verkan
- Enzyminhibitorer
- Antineoplastiska medel
- Antineoplastiska medel, immunologiska
- Angiogeneshämmare
- Angiogenesmodulerande medel
- Tillväxtämnen
- Tillväxthämmare
- Proteinkinashämmare
- Erlotinib hydroklorid
- Bevacizumab
Andra studie-ID-nummer
- CDR0000529756
- U10CA032102 (U.S.S. NIH-anslag/kontrakt)
- S0635 (Annan identifierare: SWOG)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .